SCHEMBL29133766

SCHEMBL29133766

N#Cc1cnc2ccc(Br)cc2c1NCCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 3/20 0.57
CDK8 P49336 3/20 0.57
CDKN1A P38936 1/20 0.51
CDK19 Q9BWU1 1/20 0.51
MAP3K8 P41279 1/20 0.46
HTT P42858 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
PDPK1 O15530 1/20 0.45
EGFR P00533 9/20 0.44
ERBB2 P04626 8/20 0.44
MAP2K1 Q02750 2/20 0.43
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
RAF1 P04049 1/20 0.42
GAK O14976 1/20 0.42
ABL1 P00519 1/20 0.41
SRC P12931 1/20 0.41
FLT1 P17948 1/20 0.41
KDR P35968 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29133731 0.81 EGFR (0.63) CCNCCDK8CDKN1ACDK19MAP3K8
SCHEMBL29133710 0.81 CYP1A2 (0.52) CCNCCDK8CDKN1ACDK19SMN1; SMN2
SCHEMBL29133717 0.81 EGFR (0.50) CCNCCDK8CDKN1ACDK19MAP3K8
SCHEMBL29133738 0.80 CCNC (0.47) CCNCCDK8CDKN1ACDK19MAP3K8
SCHEMBL29133761 0.80 EGFR (0.51) CCNCCDK8CDKN1ACDK19MAP3K8
SCHEMBL29133698 0.79 MELK (0.54) CCNCCDK8CDKN1ACDK19MAP3K8
SCHEMBL29133767 0.79 EGFR (0.44) CCNCCDK8CDKN1ACDK19MAP3K8
SCHEMBL29133722 0.79 MELK (0.54) CCNCCDK8CDKN1ACDK19MAP3K8
SCHEMBL29133792 0.78 PDPK1 (0.42) CCNCCDK8CDKN1ACDK19MAP3K8
SCHEMBL29133770 0.78 PIK3CA (0.54) SMN1; SMN2EGFRMAP2K1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117295716-A Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors 麦克尼斯迪克治疗有限公司 2023-12-26 CN disclosed